Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of esketamine on postoperative cognitive function in partial hepatic resection with controlled low central venous pressure
ChiCTR2300078120Phase 4Recruiting
- Sponsor
- The Second Hospital of Hebei Medical University
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in postoperative delirium (POD) and post-operative cognitive decline (POCD) (2 arms), sponsored by The Second Hospital of Hebei Medical University. Primary endpoints: Postoperative delirium, Postoperative cognitive function and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)post-operative cognitive decline (POCD)
Beyond the preview
Go deeper on ChiCTR2300078120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078120.